Skip to content

NASDAQ · large · thesis board

BIIB Biogen

Anti-amyloid and neurology portfolio

View race

Thesis

Editorial summary — not a primary filing

Alzheimer franchise defense and next assets; cash-rich but growth depends on uptake and pipeline.

Next gate

2026-10-20Company-guidedlabel expand

Subcutaneous / label update

68 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~20 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~684d)100%
Days to gate (68d)10%
Show math

$4.5B cash ÷ $200M/mo burn ≈ 684 days. Source: curated SEC quarter figures.

Cash $4.5B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
LLYApprovedokAVXLPh3okANVSPh3ok

Risks

  • Commercial competition vs Lilly
  • Safety monitoring
  • Pipeline concentration
  • Payer pressure

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03887455as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01